Evaluation of ¹⁷⁷Lu-Labeled Lipiodol as a Targeted Radionuclide Therapy for Hepatocellular Carcinoma in a Preclinical Xenograft Model.

ABSTRACT:

Background

Lutetium-177 (¹⁷⁷Lu) is a promising radionuclide for targeted cancer therapy due to its favorable theranostic properties. Transarterial lipiodol embolization is widely used for hepatocellular carcinoma (HCC), but the potential of ¹⁷⁷Lu emulsified into lipiodol (¹⁷⁷Lu-lipiodol) remains underexplored. This study aimed to evaluate the partition coefficient, biodistribution, and antitumor efficacy of ¹⁷⁷Lu-lipiodol in a preclinical xenograft model.

Methods

After synthesizing ¹⁷⁷Lu-oxine from ¹⁷⁷Lu-chloride, the product was emulsified in lipiodol. Its radiochemical purity and partition coefficient were measured. F344 NJcl rnu/nu rats (n = 5) bearing bilateral thigh tumors (HC-4 cells) were randomized to

SUBMITTER: Kono Y 

PROVIDER: S-EPMC12405020 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature